KYNB Kyntra Bio Inc.

$KYNB elected Andrew Singer as a Class III director, adding him to the Audit Committee effective Oct. 1.

$KYNB fkr those that did not listen to it. It was nothing but bla bla bla bla bla ...water under the bridge

$KYNB Upcoming Events. H.C. Wainwright 28th Annual Global Investment Conference. September 15, 2026.

$KYNB Yesterday was a very interesting trading day: the trading volume amounted to 83,886 shares. For comparison, on regular days it’s about 5–6 thousand. What was that?

$KYNB Here is what Kyntra Bio is likely doing right now, followed by the typical timeline for the Nasdaq hearing process: requested a hearing within the mandatory 7-day window following its September 30, 2026 delilisting asdaq listing through three core actions: • Staying listed: Shares continue trading under KYNB during review. • Drafting compliance plan: Writing a strategy to rebuild asset and revenue minimums. • Targeting tier transfer: Preparing to move down to the Nasdaq Capital Market. • Advancing clinical trials: Accelerating Q4 milestones to prove company viability. The average Nasdaq hearing timeline spans 2 to 2.5 months total: • Setting the date: 1 to 2 weeks for Nasdaq to respond. • The actual hearing: Scheduled 30 to 45 days from request. • The final decision: Issued 2 to 4 weeks after the hearing.